# US 2023/0313264 A1 · Assay and method for measuring alkaline phosphatase activity in urine as an index of tissue zinc deficiency

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0313264 A1
- Document ID: US20230313264A1
- Status: Published application
- Kind: A1
- Application number: 18/011,545
- Filed: 2021-07-01
- Published: 2023-10-05
- Earliest claimed: 2020-07-01
- Assignees: Vision Diagnostics, Inc.
- Applicants: Vision Diagnostics, Inc.
- Inventors: JERRY W. DENNEY
- Web page: https://patentgrep.com/patent/US20230313264A1

## CPC

- C12Q 1/42: involving phosphatase
- G01N 33/84: involving inorganic compounds or pH
- G01N 2333/916: acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
- G01N 2800/02: Nutritional disorders
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

A kit comprising two reagents for conducting two different Assays to measure a zinc-activated enzyme in a bodily fluid. The assay results are utilized to obtain a relative zinc-activated enzyme activity value that can be correlated to tissue zinc levels. A more specific embodiment utilizes two paired reagents for conducting an A Assay and a B Assay that measure different alkaline phosphatase (ALP) activities in a urine sample to obtain a Relative Renal Alkaline Phosphatase Activity (RRAPA) value. The RRAPA value can be correlated to zinc levels in renal tissue.

## Claims

### Claim 1

A kit, for obtaining a Relative Renal Alkaline Phosphatase Activity (RRAPA) value for a urine sample, comprising:
a Reagent I comprising,
a non-reactive sub-reagent comprising zinc sulfate,
a reactive sub-reagent comprising N-nitrophenylphosphate;
a Reagent II comprising,
a non-reactive sub-reagent having a composition identical to the non-reactive sub-reagent of Reagent I, without the zinc sulfate; and
a reactive sub-reagent having a composition identical to the reactive sub-reagent of Reagent I,
wherein, the results obtained from Reagent I and the results obtained with Reagent II are utilized in a RRAPA Equation to obtain the RRAPA value.

### Claim 2 (depends on 1)

The kit according to claim 1, wherein Reagent I and Reagent II further comprise a detergent.

### Claim 3 (depends on 2)

The kit according to claim 2, wherein the detergent comprises at least one of Brij 35 and Triton-X 100.

### Claim 4 (depends on 3)

The kit according to claim 3, wherein Reagent I and Reagent II further comprise a preservative.

### Claim 5 (depends on 3)

The kit according to claim 3, wherein Reagent I and Reagent II are configured for use with an automated clinical chemistry analyzer.

### Claim 6 (depends on 1)

A method for utilizing an assay to obtain a Relative Renal Alkaline Phosphatase Activity (RRAPA) value for a urine sample, the method comprising:
obtaining a kit, according to claim 1,
conducting an A Assay comprising,
combining a first portion of the urine sample with the non-reactive sub-reagent of Reagent I,
waiting a pre-determined time,
adding further the reactive sub-reagent of Reagent 1 to the first portion of the urine,
measuring spectrophotometrically an amount of N-nitrophenol formed after adding the reactive sub-reagent;
conducting a B Assay comprising,
combining a second portion of the urine sample with the non-reactive sub-reagent of Reagent II,
waiting a pre-determined time,
adding further the reactive sub-reagent of Reagent II to the second portion of the urine
measuring spectrophotometrically the N-nitrophenol formed after adding the reactive sub-reagent;
utilizing the results of the A Assay and the B Assay in the following equation:
RRAPA value= (Result of the B Assay/Result of the A Assay) * 100,
wherein the RRAPA value corresponds to the activity of alkaline phosphatase in the urine sample.

### Claim 7 (depends on 6)

The method according to claim 6, further comprising centrifuging the urine sample to obtain a supernatant and utilizing a first portion of the supernatant for conducting the A Assay and utilizing a second portion of the supernatant to form the B Assay.

### Claim 8 (depends on 7)

The method according to claim 7, wherein the first portion of supernatant comprises about 9% of a total volume of Reagent I.

### Claim 9 (depends on 8)

The method according to claim 8, wherein the second portion of supernatant comprises about 9% of the total volume of Reagent II.

### Claim 10 (depends on 6)

The method according to claim 6, further comprising utilizing a weighting factor with the measurement obtained with the A Assay.

### Claim 11 (depends on 10)

The method according to claim 10, wherein the weight factor is between about 3, 4, and 5.

### Claim 12 (depends on 11)

The method according to claim 11, wherein the A Assay and the B Assay are performed with an automated clinical chemistry analyzer programmed to calculate the RRAPA value.

### Claim 13 (depends on 12)

The method according to claim 12, further comprising programming the automated clinical chemistry analyzer with a numeric factor.

### Claim 14 (depends on 13)

The method according to claim 13, wherein the RRAPA value is correlated to a zinc level in renal tissue.

### Claim 15

A kit, for obtaining a Relative Zinc-Activated Enzyme Activity (RZAEA) value for a zinc-activated tissue enzyme in a bodily fluid sample, comprising:
a Reagent I comprising a composition that includes zinc for measuring the total activity of the zinc-activated enzyme in the bodily fluid sample; and
a Reagent II comprising a composition that is identical to the composition of Reagent I, but without zinc, for measuring the native-activity of the zinc-activated enzyme in the bodily fluid sample.

### Claim 16 (depends on 15)

The kit according to claim 15, wherein the results obtained from Reagent I and the results obtained with Reagent II are utilized in a RZAEA equation to obtain the RZAEA value.

### Claim 17 (depends on 16)

The kit according to claim 16, wherein the RZAEA value is correlated to a zinc level in a body tissue.

### Claim 18 (depends on 15)

The kit according to claim 15, wherein Reagent I further comprises a non-reactive sub-reagent and a reactive sub-reagent, and wherein Reagent II further comprises a non-reactive sub-reagent and a reactive sub-reagent.

### Claim 19 (depends on 15)

A method for utilizing an assay to obtain a Relative Zinc-Activated Enzyme Activity (RZAEA) value for a bodily fluid sample, the method comprising:
obtaining a kit according to claim 15,
conducting an A Assay comprising,
combining a first portion of the bodily fluid sample with Reagent I,
measuring spectrophotometrically a product formed by the zinc-activated enzyme, after a pre-determined period;
conducting a B Assay comprising,
combining a second portion of the bodily fluid sample with Reagent II;
measuring spectrophotometrically the product formed by the zinc-activated enzyme, after a pre-determined period;
utilizing the results of the A Assay and the B Assay in the following equation:
RZAEA value= (Result of the B Assay/Result of the A Assay) * 100,
wherein the RZAEA value corresponds to the activity of the zinc-activated enzyme in the bodily fluid sample.

### Claim 20 (depends on 19)

The method according to claim 19, wherein Reagent I further comprises a non-reactive sub-reagent and a reactive sub-reagent, and the method further comprises adding the non-reactive sub-reagent to the bodily fluid sample and subsequently adding the reactive sub-reagent to initiate formation of the product.

### Claim 21 (depends on 20)

The method according to claim 20, wherein Reagent II further comprises a non-reactive sub-reagent and a reactive sub-reagent, and the method further comprises adding the non-reactive sub-reagent to the bodily fluid sample and subsequently adding the reactive sub-reagent to initiate formation of the product.

### Claim 22 (depends on 19)

The method according to claim 19, wherein the A Assay and the B Assay are performed with an automated clinical chemistry analyzer programmed to calculate the RZAEA value.

### Claim 23 (depends on 22)

The method according to claim 22, wherein the RZAEA value is correlated to a zinc level in tissue.
